October 15,Wave Life Sciences stated in an SEC filing that Takeda had, in October,On the 11th, it was decided to abandon the exercise of options for Huntington's disease therapies, including WVE-003.InvolveHuntington's Disease TreatmentLegalThe strategic cooperation agreement was signed in February 2018 and revised in October 2021.. The content of the 2018 collaboration focused on the discovery, development, and commercialization of treatments for central nervous system disorders, includingHuntingtonShi's disease,Amyotrophic Lateral Sclerosis,Frontotemporal Dementia,Spinocerebellar Ataxia Type 3, Alzheimer's Disease, Parkinson's Disease) nucleic acid drug.Since the beginning of the collaboration, Takeda has providedWave Life SciencesPaid approximately $260 million.
WVE-003 isWave Life SciencesThe only active pipeline in researchHuntington's disease therapy, which was also the last unannounced failure resulting from previous collaboration agreements.In June this year,Wave Life ScienceWave Life Sciences Ltd. announced the Phase I/II clinical trial of WVE-003 for the treatment of Huntington's disease.SELECT-HDResearch Data.The results showed,WVE-003 (30mg, once every 8 weeks) groupPatient'sMutant Huntingtin Protein (mHTT) LevelsCompared withSignificant in the placebo groupDecrease (at Week 24 of treatment, mHTT was reduced by 46%)；At Week 28 of treatment, mHTT was reduced by 44%.）。Wave Life Sciences believes,Sales of WVE-003 are expected to reach $5 billion, while the commercial value of other Single Nucleotide Polymorphism (SNP) projects could expand to $10 billion.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
